Blood test could revolutionize Alzheimer's diagnosis at your Doctor's office

NCT ID NCT07666113

Recruiting now Diagnosis Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that measures specific proteins (pTau217) can help primary care doctors diagnose Alzheimer's disease in people with memory concerns. Researchers will compare the test's accuracy against standard evaluations and track how it changes doctors' decisions and patient outcomes over four years. The goal is to make Alzheimer's diagnosis faster, less invasive, and more accessible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood test measuring pTau217 and pTau217/Aβ42 levels
What this could lead to: If successful, this blood test could help primary care doctors diagnose Alzheimer's earlier and more accurately, reducing the need for specialist referrals and invasive tests.
What could go wrong: This is an early-stage study with only 240 participants. The test may not be accurate enough in real-world primary care settings, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE(AD)

Contacts and locations

Locations

UZ Leuven/KU Leuven
RECRUITING

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.